Statins in multiple sclerosis: A new therapeutic option?

Multiple Sclerosis

Volumn 9, Issue 5, 2003, Pages 429-430

  Neuhaus, Oliver ^a   Archelos, J J ^b   Hartung, H P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTILIPEMIC AGENT; ATORVASTATIN; COMPACTIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON BETA SERINE; INTERLEUKIN 12; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVALONIC ACID; MEVINOLIN; MYELIN; RHO KINASE; SIMVASTATIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; EXPERIMENTAL MODEL; HUMAN; HYPERCHOLESTEROLEMIA; LYMPHOCYTE TRANSFER; MORBIDITY; MULTIPLE SCLEROSIS; NONHUMAN;

CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MULTIPLE SCLEROSIS;

EID: 0142091873     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms952ed     Document Type: Editorial

References (18)

1. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3: 291-301.
2. Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis: From immunosuppression to neuroprotection. Trends Pharmacol Sci 2003; 24: 131-38.
3. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550-57.
4. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996; 34: 51-61.
5. Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 2001; 66: 155-62.
6. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
7. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725-33.
8. Greenwood J, Walters CE, Pryce G, Kanunga N, Beraud E, Baker D et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003 10.1096/fj.02-1014fje.
9. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP et al. Statins as immunomodulators: Comparison with interferon-beta1b in MS. Neurology 2002; 59: 990-97.
10. Vollmer T, Durkalski V, Tyor W, Corboy J, Preiningerova J, Markovic-Plese S et al. An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS). Neurology 2003; 60(Suppl 1): A84 (abstract).
11. Baker D, Adamson P, Greenwood J. Potential of statins for the treatment of multiple sclerosis. Lancet Neurol 2003; 2: 9-10.
12. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-19.
13. Weitz-Schmidt S. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002; 23: 482-86.
14. Singh R, Wang B, Shirvaikar A, Khan S, Kamat S, Schelling JR et al. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J Clin Invest 1999; 103: 1561-70.
15. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
16. Archelos JJ, Hartung HP. The role of adhesion molecules in multiple sclerosis: Biology, pathogenesis and therapeutic implications. Mol Med Today 1997; 3: 310-21.
17. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402.
18. Wekerle H. Tackling multiple sclerosis. Nature 2002; 420: 39-40.